

Risk-adapted Therapy for PV

References

1. Spivak JL. How I treat polycythemia vera. *Blood*. 2019;134(4):341-352.
2. Wang L, Swierczek SI, Lanikova L, et al. The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera. *Leukemia*. 2014;28(4):938-941.
3. Cassinat B, Laguillier C, Gardin C, et al. PV-Nord Group. Classification of myeloproliferative disorders in the JAK2 era: Is there a role for red cell mass? *Leukemia*. 2008;22(2):452-453.
4. Stein BL, Williams DM, Wang N-Y, et al. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. *Haematologica*. 2010;95(7):1090-1097.
5. McNally RJ, Rowland D, Roman E, et al. Age and sex distributions of hematological malignancies in the U.K. *Hematol Oncol*. 1997;15(4):173-189.
6. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. *Blood*. 2015;126(1):9-16.
7. Stein LB, Rademaker A, Spivak JL, et al. Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms. *Thrombosis*. 2011;2011;874146.
8. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. *Blood Cancer J*. 2018;8(1):3.
9. Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms. *N Engl J Med*. 2018;379(15):1416-1430.
10. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: A Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. *Semin Hematol*. 1997;34(1):17-23.
11. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. *N Engl J Med*. 1981;304(8):441-447.
12. Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980. *J Clin Oncol*. 2011;29(29):3907-3913.
13. Spivak JL. Myeloproliferative neoplasms. *N Engl J Med*. 2017;376(22):2168-2181.
14. Lamy T, Devillers A, Bernard M, et al. Inapparent polycythemia vera: An unrecognized diagnosis. *Am J Med*. 1997;102(1):14-20.
15. Pearson TC, Guthrie DL, Simpson J, et al. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. *Br J Haematol*. 1995;89(4):748-756.
16. Masarova L, Yin CC, Cortes JE, et al. Histomorphological responses after therapy with pegylated interferon a-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). *Exp Hematol Oncol*. 2017;6:30.
17. Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): A randomised, open-label, phase 3b study. *Lancet Oncol*. 2017;18(1):88-99.
18. Masarova L, Verstovsek S, Hidalgo-Lopez JE, et al. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. *Blood*. 2018;132(16):1664-1674.
19. McNeil JJ, Wolfe R, Woods RL, et al; ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. *N Engl J Med*. 2018;379(16):1509-1518.